Triple negative breast cancer accounts for approximately 15 per cent of all breast cancers and refers to a type of breast cancer that does not have any of the three receptors commonly found in breast cancer cells – the oestrogen, progestogen and HER2 receptors.
Although triple negative breast cancer does not respond to hormone-blocking therapy or medicines that target HER2 protein receptors, chemotherapy is often used to successfully treat this form of breast cancer, with active research taking place to improve treatments to better target triple negative breast cancer.
We heard from Medical Oncologist Nick Zdenkowski who has a special interest in the care of patients with breast cancer and offers the latest medical oncology treatments. Additionally, we also heard from BCNA consumer representative Emma Warnecke.
This Ask the Expert session addressed what triple negative is including the different subtypes, the current treatments available and the outcomes including risk of recurrence, genetic testing and implications and the clinical research trials and how to access them, plus much more.
To help improve our digital events and ensure we provide information that you're interested in, we invite you to complete our 2-minute survey.
Immunotherapy (or biological/biologic therapy) helps the body fight cancer by blocking checkpoint proteins. Understand how it works
New and emerging treatments for MBC
Targeted (or biological/biologic) therapy blocks the growth and spread of cells. It may be used for all forms of metastatic breast cancer
The process to assess and consider breast cancer medicines for subsidy on the PBS and ways to access non-subsidised medicines
Women who develop breast cancer at any age before menopause may need to consider challenges such as fertility, and treatment while pregnant
Latest treatments and the pioneering research shaping the future
About radiation, managing side effects, follow-up care and costs